Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo - Possible involvement of different mechanisms

European Neuropsychopharmacology

Volumn 15, Issue 1, 2005, Pages 103-110

  Daniel, W A ^a   Haduch, A ^a   Wojcikowski J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

CYP2D; Haloperidol; Phenothiazines; Rat; Risperidone; Sertindole

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2D; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERAZINE; PROMAZINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE;

ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; LIVER MICROSOME; LONG TERM EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETHYLMORPHINE; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; TIME FACTORS;

EID: 9644275590     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.05.008     Document Type: Article

References (77)

1. Basu S., Dasgupta P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102:2000;113-124
2. Baum L.O., Strobel H.W. Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones. Brain Res. 765:1997;67-73
3. Blake B.L., Rose R.L., Mailman R.B., Levi P.E., Hodgson E. Metabolism of thioridazine by microsomal monooxygenases: relative roles of P-450 and flavin-containing monooxygenase. Xenobiotica. 25:1995;377-393
4. Bock J.L., Nelson J.C., Gray S., Jatlow P.I. Desipramine hydroxylation: effect of antipsychotic drugs. Clin. Pharmacol. Ther. 33:1983;321-328
5. Boobis A.R., Seddon C.E., Davies D.S. Bufuralol 1′-hydroxylase activity of the rat. Biochem. Pharmacol. 35:1986;2961-2965
6. Boobis A.R., Sesardic D., Murray B.P., Edwards R.J., Singleton A.M., Rich K.J., Murray S., de la Torres R., Seguras J., Pelkonen O., Pasanen M., Kobayashi S., Zhi-Guang T., Davies D.S. Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica. 20:1990;1139-1161
7. Brockmoller J., Kirchheiner J., Schmider J., Walter S., Sachse C., Müller-Örlinghausen B., Roots J. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharamacol. Ther. 72:2002;438-452
8. Brøsen K., Gram L.F., Klysner R., Bech P. Steady-state levels of imipramine and ist metabolites: significance of dose-dependent kinetics. Eur. J. Clin. Pharmacol. 30:1986;43-49
9. Chow T., Imaoka S., Hiroi T., Funae Y. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab. Dispos. 27:1999;188-192
10. Coleman T., Ellis S.W., Martin I.J., Lennard M.M., Tucker G.T. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P-450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 227:1996;685-690
11. Dahl M.L., Bertilsson L. Genetically variable metabolism of antidepressant and neuroleptic drugs. Pharmacogenetics. 3:1993;61-70
12. Dahl-Puustinen M.L., Liden A., Alm C., Nordin C., Bertilsson L. Disposition of perphenazine is related to the polymorphic hydroxylation in human beings. Clin. Pharmacol. Ther. 46:1989;78-81
13. Daniel W. Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats. Pol. J. Pharmacol. Pharm. 43:1991;197-202
14. Daniel W., Melzacka M. The effect of neuroleptics on imipramine demethylation in rat liver microsomes and imipramine and desipramine level in the rat brain. Biochem. Pharmacol. 35:1986;3249-3253
15. Daniel W.A., Syrek M., Haduch A., Wójcikowski J. Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. Br. J. Pharmacol. 131:2000;287-295
16. Daniel W.A., Syrek M., Haduch A., Wójcikowski J. Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. J. Pharm. Pharmacol. 52:2000;1473-1481
17. Daniel W.A., Haduch A., Wójcikowski J. Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J. Pharm. Pharmacol. 54:2002;1545-1552
18. Daniel W.A., Syrek M., Haduch A. The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. Eur. Neuropsychopharmacol. 12:2002;371-377
19. de Mol N.J., Busker R.W. Irreversible binding of the chlorpromazine radical cation and of photoactivated chlorpromazine to biological macromolecules. Chem. Biol. Interact. 52:1984;79-92
20. de Mol N.J., Becht A.B.C., Koenen J., Lodder G. Irreversible binding with biological macromolecules and effect of bacterial mutagenity tests on the radical cation of promethazine and photoactivated promethazine. Comparison with chlorpromazine. Chem. Biol. Interact. 57:1986;73-83
21. Eap C.B., Bondolfi G., Zullino D., Bryois C., Fuciec M., Savary L., Jonzier-Perry M., Baumann P. Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther. Drug Monit. 23:2001;228-231
22. Ellingrod V.L., Schultz S.K., Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (aims) score. Psychiatr. Genet. 10:2000;9-11
23. Fang J., Gorrod J.W. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell. Mol. Neurobiol. 19:1999;491-510
24. Fang J., Mckay G., Song J., Remillrd A., Xinmin L.I., Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab. Dispos. 12:2001;1638-1643
25. Forrest I.S., Green D.E. Phenothiazines: metabolism and analytical detection. J. Forens. Sci. 17:1972;592-617
26. Gilham D.E., Cairns W., Paine M.J.I., Modi S., Poulsom R., Roberts G.C.K., Wolf C.R. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybrydization. Xenobiotica. 27:1997;111-125
27. Glare P.A., Walsh T.D., Pippenger C.E. A simple, rapid method for the simultenaous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther. Drug Monit. 13:1991;226-232
28. Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P., Meyer U.A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 331:1988;442-446
29. Gram L.F., Christiansen J., Overø K.F. Pharmacokinetic interaction between neuroleptics and tricyclic antidepressants in the rat. Acta Pharmacol. Toxicol. 35:1974;223-232
30. Gram L.F., Overø K.F., Kirk L. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am. J. Psychiatry. 131:1974;863-44-55
31. Gutierrez-Correa J., Stoppani A.O. Mycloperoxidase-generated phenothiazine cation radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase. Rev. Argent. Microbiol. 34:2002;83-94
32. Gutierrez-Correa J., Fairlamb A.H., Stoppani A.O. Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals. Rev. Argent. Microbiol. 33:2001;36-46
33. Gutierrez-Correa J., Fairlamb A.H., Stoppani A.O. Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic. Res. 34:2001;363-378
34. Hals P.A., Dahl S.G. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. Pharmacol. Toxicol. 75:1994;255-260
35. Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6 biochem. Biophys. Res. Commun. 249:1998;838-843
36. Hiroi T., Kishimoto W., Chow T., Imaoka S., Igarashi T., Funae Y. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology. 142:2001;3901-3908
37. Hiroi T., Chow T., Imaoka S., Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab. Dispos. 30:2002;970-976
38. Huang M.L., van Peer A., Woestenborghs R., de Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54:1993;257-268
39. Jerling M., Dahl M.-L., Aberg-Wisted A., Liljenberg B., Landell N.-E., Bertilsson L. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin. Pharmacol. Ther. 59:1996;423-428
40. Kelder P.P., Fischer M.J.E., de Mol N.J., Janssen L.H.M. Oxidation of chlorpromazine by methemoglobin in the presence of hydrogen peroxide. Formation of chlorpromazine radical cation and its covalent binding to methemoglobin. Arch. Biochem. Biophys. 284:1991;313-319
41. Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzalez F.J. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45:1989;889-904
42. Kobayashi S., Murray S., Watson D., Sesardic D., Davies D.S., Boobis A.R. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38:1989;2795-2799
43. Kroemer H.K., Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56:1995;2285-2298
44. Kupfenberg H., Burkhalter A., Way E.L. A sensitive fluorometric assay for morphine in plasma and brain. J. Pharmacol. Exp. Ther. 145:1964;247-251
45. Kurokohchi K., Yoneyama H., Matsuo Y., Nishioka M., Ichikawa Y. Effects of interleukin 1α on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem. Pharmacol. 44:1992;1669-1674
46. Llerna A., Herraiz E.G., Cobaleda J., Johansson I., Dahl M.-L. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54:1996;606-611
47. Llerna A., Berecz R., de la Rubia A., Norberto M.J., Benitez J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther. Drug Monit. 22:2000;397-401
48. Llerna A., Berecz R., de la Rubia A., Fernandez-Salguero P., Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 23:2001;616-620
49. Maj J., Baran L., Bigajska K., Rogóz Z., Skuza G. The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan. Pol. J. Pharmacol. 30:1978;431-440
50. Matsunaga E., Umeno M., Gonzalez F.J. The rat debrisoquine 4-hydroxylase CYP2D gene subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme binding region of the cytochrome P450 active site. J. Mol. Evol. 30:1990;155-169
51. Meyer J.W., Woggon B., Baumann P., Meyer U.A. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol. 39:1990;613-614
52. Morgan E.T., Sewer M.B., Iber H., Gonzalez F.J., Lee Y.-H., Tukey R.H., Okino S., Vu T., Chen Y.-H., Sidhu J.S., Omiecinski C.J. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab. Dispos. 26:1998;1232-1240
53. Muralidharan G., Cooper J.K., Hawes E.M., Korchinski E.D., Midha K.K. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolizers of debrisoquine. Eur. J. Clin. Pharmacol. 50:1996;121-128
54. Nelson J.C., Jatlow P.J. Neuroleptic effect on desipramine steady-state plasma concentration. Am. J. Psychiatry. 137:1980;1232-1234
55. Ohta S., Tachikava Y., Makino Y., Tasaki Y., Hirobe M. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ), a possible parkinsonian inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci. 46:1990;599-605
56. Rane A., Liu Z., Levol R., Bjelfman C., Thyr C., Ericson H., Hansson T., Henderson C., Wolf R.C. Differential effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat. Biochim. Biophys. Acta. 1291:1996;60-66
57. Reggiani K., Vandel P., Haffen E., Sechter D., Bizuard P., Vandel S. Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism. Encephale. 26:2000;62-67
58. Schulz-Utermoehl T., Bennett A.J., Ellis S.W., Tucker G.T., Boobis A.R., Edwards R.J. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics. 9:1999;357-366
59. Scordo M.G., Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 3:2002;201-218
60. Scordo M.G., Spina E., Romeo P., Dahl M.L., Bertilsson L., Johansson J., Sjoqvist F. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur. J. Clin. Pharmacol. 56:2000;679-683
61. Shin J.C., Soukhova N., Flockhart D.A. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab. Dispos. 27:1999;1078-1084
62. Shin J.G., Kane K., Flockhart D.A. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br. J. Clin. Pharmacol. 51:2001;45-52
63. Steiner E., Dumond E., Spina E., Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43:1988;577-581
64. Syvälahti E.K.G., Lindberg R., Kallio J., de Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br. J. Pharmacol. 22:1986;89-92
65. Tateishi T., Kumai T., Watanabe M., Tanaka M., Kobayashi S. A comparison of the effect of five phenothiazines on hepatic CYP isoenzymes in rats. Pharmacol. Toxicol. 85:1999;252-256
66. Thompson C.M., Capdevila J.H., Strobel H.W. Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J. Pharmacol. Exp. Ther. 294:2000;1120-1130
67. Trautwein C., Ramadori G., Gerken G., Meyer zum Büschenfelde K.H., Manns M. Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice. Biochem. Biophys. Res. Commun. 182:1992;617-623
68. Tyndale R.F., Li Y., Li N.-Y., Messina E., Miksys S., Sellers E.M. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27:1999;924-930
69. Vandel B., Vandel S., Allers G., Bechtel P., Volmat R. Interaction between amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology. 65:1979;187-190
70. Vandel P., Haffen E., Vandel S., Bonin B., Nezelof S., Sechter D., Broly F., Bizuard P., Dalery J. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur. J. Clin. Pharmacol. 55:1999;659-665
71. Wan J., Imaoka S., Chow T., Hiroi T., Yabusaki Y., Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch. Biochem. Biophys. 348:1997;383-390
72. Waxman D.J. Interactions of hepatic cytochromes P-450 with steroid hormones. Biochem. Pharmacol. 37:1988;71-84
73. Wong S.L., Menacherry S., Mulford D., Schmitz P.J., Locke C., Granneman G.R. Parmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur. J. Clin. Pharmacol. 52:1997;223-227
74. Xu B.Q., Aassmundstad T.A., Bjørneboe A., Christofersen A.S., Mørland J. Ethylmorphine O-deethylation in isolated rat hepatocytes. Biochem. Pharmacol. 49:1995;453-460
75. Yamamoto Y., Tasaki T., Nakamura A., Jawata H., Kazusaka A., Gonzalez F.J., Fujita S. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics. 8:1998;73-82
76. Yoshii K., Kobayashi K., Tsumuji M., Tani M., Shimada N., Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 67:2000;175-184
77. You A.-M., Idle J.R., Byrd L.G., Krausz K.W., Küpfer A., Gonzalez F.J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 13:2003;173-181